Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 12/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20356732 | 0.85 | HRH3 (0.62) | HRH3MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL20443001 | 0.84 | ALDH1A1 (0.54) | HRH3MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL25728960 | 0.84 | CYP1A2 (0.63) | HRH3MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL10289221 | 0.83 | LMNA (0.51) | HRH3MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL12651283 | 0.81 | HRH3 (0.53) | CXCR4HRH3MEN1KMT2ACYP1A2 | |
| SCHEMBL14307263 | 0.81 | CXCR4 (0.53) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL31639376 | 0.81 | CXCR4 (0.48) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL22642421 | 0.80 | CXCR4 (0.47) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL21414344 | 0.80 | HRH3 (0.46) | HRH3MEN1CHRM1KMT2ACYP1A2 | |
| SCHEMBL21414342 | 0.79 | RAB9A (0.55) | HRH3MEN1KMT2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| EP-3546458-B1 | ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER | TEIJIN PHARMA LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| EP-3546458-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2019-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | CXCR4 702/4885HRH3 2223/4885MEN1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.